MX389600B - Nueva composición terapéutica que contiene ingrediente activo de apomorfinas. - Google Patents

Nueva composición terapéutica que contiene ingrediente activo de apomorfinas.

Info

Publication number
MX389600B
MX389600B MX2014000454A MX2014000454A MX389600B MX 389600 B MX389600 B MX 389600B MX 2014000454 A MX2014000454 A MX 2014000454A MX 2014000454 A MX2014000454 A MX 2014000454A MX 389600 B MX389600 B MX 389600B
Authority
MX
Mexico
Prior art keywords
composition containing
apomorphins
active ingredient
therapeutic composition
containing active
Prior art date
Application number
MX2014000454A
Other languages
English (en)
Other versions
MX2014000454A (es
Inventor
Marie-Madeleine Baronnet
Laurent Bertocchi
Michael Dey
Jeremiah Harnett
Nathalie Mondoly
Joel Richard
Original Assignee
Britannia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britannia Pharmaceuticals Ltd filed Critical Britannia Pharmaceuticals Ltd
Publication of MX2014000454A publication Critical patent/MX2014000454A/es
Publication of MX389600B publication Critical patent/MX389600B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que contiene apomorfina como principio farmacéutico activo, codisolvente, antioxidante, agua con un pH mayor que 4. La formulación farmacéutica es adecuada para la administración parenteral para el tratamiento de la enfermedad de Parkinson.
MX2014000454A 2011-07-11 2012-07-11 Nueva composición terapéutica que contiene ingrediente activo de apomorfinas. MX389600B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11290320A EP2545905A1 (en) 2011-07-11 2011-07-11 A new therapeutical composition containing apomorphine as active ingredient
PCT/EP2012/002916 WO2013007381A1 (en) 2011-07-11 2012-07-11 A new therapeutical composition containing apomorphine as active ingredient

Publications (2)

Publication Number Publication Date
MX2014000454A MX2014000454A (es) 2014-09-01
MX389600B true MX389600B (es) 2025-03-19

Family

ID=46514305

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014000454A MX389600B (es) 2011-07-11 2012-07-11 Nueva composición terapéutica que contiene ingrediente activo de apomorfinas.
MX2021010046A MX2021010046A (es) 2011-07-11 2014-01-10 Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010046A MX2021010046A (es) 2011-07-11 2014-01-10 Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.

Country Status (30)

Country Link
US (4) US11026938B2 (es)
EP (2) EP2545905A1 (es)
JP (2) JP6356064B2 (es)
KR (1) KR101990897B1 (es)
CN (2) CN108434094A (es)
AU (1) AU2012283381B2 (es)
BR (1) BR112014000306B1 (es)
CA (1) CA2841807C (es)
CL (1) CL2014000050A1 (es)
CO (1) CO6870038A2 (es)
CR (1) CR20140005A (es)
CU (1) CU24159B1 (es)
DO (1) DOP2014000003A (es)
EA (1) EA025870B1 (es)
EC (1) ECSP14013200A (es)
GE (2) GEP20196969B (es)
GT (1) GT201400003A (es)
IL (1) IL230308A (es)
IN (1) IN2014DN00090A (es)
MA (1) MA35411B1 (es)
MX (2) MX389600B (es)
MY (1) MY168212A (es)
NI (1) NI201400003A (es)
PE (1) PE20141539A1 (es)
PH (1) PH12014500065A1 (es)
SG (1) SG10201605491PA (es)
TN (1) TN2014000001A1 (es)
UA (1) UA113962C2 (es)
WO (1) WO2013007381A1 (es)
ZA (1) ZA201309711B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
AU2013273138B2 (en) * 2012-06-05 2017-06-15 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
EP2918266A1 (en) 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
EP2979688A1 (en) * 2014-08-01 2016-02-03 Britannia Pharmaceuticals Limited Composition containing Apomorphine and a Divalent Metal Cation
EP3237386A2 (en) * 2014-12-23 2017-11-01 Neuroderm Ltd Crystal forms of apomorphine and uses thereof
MA43042A (fr) * 2015-09-28 2018-08-08 Ever Neuro Pharma Gmbh Composition aqueuse d'apomorphine pour une administration sous-cutanée
WO2020243538A1 (en) * 2019-05-31 2020-12-03 Primo Pharmatech Llc Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient
WO2021026421A1 (en) * 2019-08-07 2021-02-11 Aclipse One Inc. Pharmaceutical compositions of (6as)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol
GB201912686D0 (en) * 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition
CN115666571B (zh) 2020-05-20 2024-11-05 美德阿利克斯株式会社 含有阿扑吗啡的经皮吸收型制剂
WO2022271537A1 (en) * 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
US20240335379A1 (en) * 2021-08-05 2024-10-10 Zydus Lifesciences Limited Stable pharmaceutical compositions of apomorphine
US20250361252A1 (en) 2022-06-15 2025-11-27 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1662566A1 (ru) * 1988-03-05 1991-07-15 Всесоюзный Научно-Исследовательский Институт Биотехнологии Способ стабилизации инъекционного раствора апоморфина
JP2822049B2 (ja) * 1989-02-02 1998-11-05 ゼリア新薬工業株式会社 水性製剤組成物
US5756483A (en) * 1993-03-26 1998-05-26 Merkus; Franciscus W. H. M. Pharmaceutical compositions for intranasal administration of apomorphine
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US6011043A (en) 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
US20020169166A1 (en) 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
US20030008878A1 (en) 2001-03-09 2003-01-09 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
ITMI20011321A1 (it) * 2001-06-22 2002-12-22 Chiesi Farma Spa Composizione farmaceutica in forma di microemulsione atta alla somministrazione per via transdermale di apomorfina utile nel trattamento del
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
US6939094B2 (en) 2003-01-28 2005-09-06 Macro Technologies Inc. Autonomous power interface for modifying limited rotation speed of a machine
CA2520121A1 (en) 2003-04-03 2004-10-21 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
US20070197602A1 (en) * 2004-02-09 2007-08-23 Hashime Kanazawa Combined pharmaceutical composition
MX2008014910A (es) 2006-05-24 2009-01-23 Bayer Schering Pharma Ag Anticuerpos bloqueantes de la funcion de la integrina ?5?1 humanos y humanizados de gran afinidad con inmunogenicidad reducida.
US20080171072A1 (en) * 2006-08-11 2008-07-17 Frank Burczynski Ocular inserts containing apomorphine
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
CN101712675B (zh) * 2008-10-07 2013-07-03 江苏恒谊药业有限公司 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient

Also Published As

Publication number Publication date
US20160310480A1 (en) 2016-10-27
CN108434094A (zh) 2018-08-24
KR101990897B1 (ko) 2019-06-19
JP2014518285A (ja) 2014-07-28
CR20140005A (es) 2014-07-21
SG10201605491PA (en) 2016-08-30
US11766431B2 (en) 2023-09-26
EP2731589A1 (en) 2014-05-21
EP2545905A1 (en) 2013-01-16
CU24159B1 (es) 2016-03-31
BR112014000306B1 (pt) 2022-03-29
MY168212A (en) 2018-10-15
CN103826612A (zh) 2014-05-28
CU20140005A7 (es) 2014-04-24
EA025870B1 (ru) 2017-02-28
NI201400003A (es) 2015-10-12
KR20140072861A (ko) 2014-06-13
US20180098981A1 (en) 2018-04-12
JP2017081947A (ja) 2017-05-18
MX2021010046A (es) 2021-09-21
IN2014DN00090A (es) 2015-05-15
EA201400067A1 (ru) 2015-02-27
US20210244724A1 (en) 2021-08-12
GEAP201813377A (en) 2018-12-25
CA2841807A1 (en) 2013-01-17
AU2012283381A1 (en) 2014-02-06
CO6870038A2 (es) 2014-02-20
MX2014000454A (es) 2014-09-01
BR112014000306A2 (pt) 2017-02-07
DOP2014000003A (es) 2014-06-01
US20140128422A1 (en) 2014-05-08
IL230308A (en) 2017-04-30
GT201400003A (es) 2017-09-28
MA35411B1 (fr) 2014-09-01
GEP20196969B (en) 2019-04-25
ZA201309711B (en) 2014-08-27
JP6356064B2 (ja) 2018-07-11
US11026938B2 (en) 2021-06-08
CL2014000050A1 (es) 2014-08-18
PH12014500065A1 (en) 2014-02-17
TN2014000001A1 (en) 2015-07-01
CA2841807C (en) 2018-02-20
PE20141539A1 (es) 2014-10-25
WO2013007381A1 (en) 2013-01-17
ECSP14013200A (es) 2014-04-30
CN103826612B (zh) 2020-07-28
AU2012283381B2 (en) 2017-07-27
UA113962C2 (xx) 2017-04-10

Similar Documents

Publication Publication Date Title
MX389600B (es) Nueva composición terapéutica que contiene ingrediente activo de apomorfinas.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
NZ608116A (en) Triazine-oxadiazoles
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201390198A1 (ru) Гетероциклическое соединение
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
NZ607580A (en) N-heteroaryl compounds
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
ME02405B (me) Spojevi pirazola као inhibitori sglt1
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
EA201490573A1 (ru) Соединение бензотиазолона
EA201491992A1 (ru) Новые соединения и новое применение
EA201590452A1 (ru) СОЛИ СОЕДИНЕНИЯ БЕНЗОТИАЗОЛОНА В КАЧЕСТВЕ АГОНИСТОВ β-2-АДРЕНОРЕЦЕПТОРОВ